Media headlines about Ardelyx (NASDAQ:ARDX) have trended positive on Monday, according to Accern. The research firm ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ardelyx earned a media sentiment score of 0.32 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 47.0264424961105 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the headlines that may have effected Accern Sentiment Analysis’s analysis:
- Knight Announces Exclusive License Agreement with Ardelyx for Tenapanor (marketwired.com)
- Ardelyx and Knight Collaborate to Bring Tenapanor to Patients in Canada (finance.yahoo.com)
- Ardelyx Inc (ARDX) Forecasted to Post FY2021 Earnings of $0.70 Per Share (americanbankingnews.com)
- Ardelyx’s (ARDX) Outperform Rating Reaffirmed at Wedbush (americanbankingnews.com)
- Technical Secrets – Ardelyx Inc (NASDAQ: ARDX) – Alpha Beta Stock (alphabetastock.com)
Ardelyx stock traded down $0.10 on Monday, reaching $5.35. The company’s stock had a trading volume of 23,584 shares, compared to its average volume of 290,586. The firm has a market cap of $259.44, a price-to-earnings ratio of -4.01 and a beta of 0.76. Ardelyx has a 12-month low of $4.05 and a 12-month high of $15.40.
A number of brokerages recently weighed in on ARDX. Wedbush reissued an “outperform” rating on shares of Ardelyx in a research note on Thursday. Cantor Fitzgerald set a $12.00 price objective on Ardelyx and gave the company a “buy” rating in a research note on Saturday. BidaskClub raised Ardelyx from a “hold” rating to a “buy” rating in a research note on Friday, January 26th. Finally, Zacks Investment Research downgraded Ardelyx from a “buy” rating to a “hold” rating in a research note on Tuesday, January 23rd. Two analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $12.93.
ILLEGAL ACTIVITY WARNING: This piece of content was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://ledgergazette.com/2018/03/19/ardelyx-ardx-given-media-impact-rating-of-0-32.html.
Ardelyx, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company’s products line includes cardiorenal portfolio and gastrointestinal portfolio.
Receive News & Ratings for Ardelyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx and related companies with MarketBeat.com's FREE daily email newsletter.